Barclays PLC Cyma Bay Therapeutics, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 15, 2024
BUY
$12.63 - $24.47 $1.85 Million - $3.59 Million
146,694 Added 336.16%
190,332 $4.5 Million
Q3 2023

Nov 07, 2023
SELL
$10.86 - $17.62 $115,148 - $186,824
-10,603 Reduced 19.55%
43,638 $651,000
Q2 2023

Aug 03, 2023
BUY
$7.47 - $10.95 $203,669 - $298,551
27,265 Added 101.07%
54,241 $594,000
Q1 2023

May 04, 2023
SELL
$5.88 - $9.59 $122,298 - $199,462
-20,799 Reduced 43.54%
26,976 $236,000
Q4 2022

Feb 13, 2023
BUY
$3.22 - $6.27 $137,564 - $267,866
42,722 Added 845.48%
47,775 $300,000
Q3 2022

Nov 03, 2022
SELL
$2.77 - $4.25 $359,823 - $552,075
-129,900 Reduced 96.26%
5,053 $18,000
Q2 2022

Aug 12, 2022
BUY
$1.72 - $3.39 $160,052 - $315,453
93,054 Added 222.09%
134,953 $398,000
Q1 2022

May 16, 2022
SELL
$2.77 - $3.64 $116,971 - $153,709
-42,228 Reduced 50.2%
41,899 $130,000
Q4 2021

Feb 14, 2022
BUY
$3.23 - $4.6 $180,217 - $256,656
55,795 Added 196.93%
84,127 $285,000
Q3 2021

Nov 09, 2021
BUY
$3.47 - $4.42 $67,137 - $85,518
19,348 Added 215.36%
28,332 $104,000
Q2 2021

Aug 13, 2021
SELL
$3.94 - $4.92 $194,360 - $242,703
-49,330 Reduced 84.59%
8,984 $40,000
Q1 2021

May 13, 2021
BUY
$4.23 - $6.55 $150,985 - $233,795
35,694 Added 157.8%
58,314 $264,000
Q4 2020

Feb 11, 2021
SELL
$5.73 - $9.03 $52,251 - $82,344
-9,119 Reduced 28.73%
22,620 $129,000
Q3 2020

Nov 12, 2020
SELL
$3.32 - $7.24 $289,045 - $630,328
-87,062 Reduced 73.28%
31,739 $230,000
Q2 2020

Aug 12, 2020
SELL
$1.41 - $4.25 $27,097 - $81,676
-19,218 Reduced 13.92%
118,801 $415,000
Q1 2020

May 13, 2020
BUY
$1.25 - $2.02 $78,247 - $126,447
62,598 Added 83.0%
138,019 $204,000
Q4 2019

Feb 10, 2020
SELL
$1.33 - $5.93 $967,350 - $4.31 Million
-727,331 Reduced 90.6%
75,421 $149,000
Q3 2019

Nov 14, 2019
BUY
$5.12 - $7.21 $2.06 Million - $2.9 Million
401,778 Added 100.2%
802,752 $4.11 Million
Q2 2019

Aug 14, 2019
BUY
$6.05 - $13.66 $2.04 Million - $4.62 Million
337,927 Added 535.99%
400,974 $2.87 Million
Q1 2019

May 15, 2019
BUY
$8.16 - $13.42 $487,152 - $801,174
59,700 Added 1783.69%
63,047 $837,000
Q4 2018

Feb 14, 2019
SELL
$6.54 - $11.74 $346,181 - $621,433
-52,933 Reduced 94.05%
3,347 $26,000
Q3 2018

Nov 14, 2018
BUY
$10.88 - $14.52 $565,292 - $754,415
51,957 Added 1201.87%
56,280 $624,000
Q2 2018

Aug 14, 2018
SELL
$10.66 - $14.38 $896,122 - $1.21 Million
-84,064 Reduced 95.11%
4,323 $58,000
Q1 2018

May 15, 2018
SELL
$9.0 - $15.16 $442,557 - $745,462
-49,173 Reduced 35.75%
88,387 $1.15 Million
Q4 2017

Feb 14, 2018
BUY
$7.67 - $9.31 $953,457 - $1.16 Million
124,310 Added 938.19%
137,560 $1.27 Million
Q3 2017

Nov 14, 2017
BUY
$5.95 - $8.26 $78,837 - $109,445
13,250
13,250 $107,000

Others Institutions Holding CBAY

# of Institutions
6
Shares Held
1.82M
Call Options Held
0
Put Options Held
0
View Full List

About CymaBay Therapeutics, Inc.

CBAY Quotes by TradingView
  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email